BD, a leading global medical technology company, today reported quarterly revenues of $5.315 billion for the first fiscal quarter
In his new role, Kurdikar will have responsibility for driving global strategic, operational and commercial performance across a portfolio of solutions that aims to minimize the burdens and complications for people with diabetes.
Insulet today announced that management will present at three upcoming virtual investor conferences:
Appointment positions Cecelia Health for accelerated growth and expansion
Seasoned Chief Financial Officer to accelerate One Drop’s expansion amid growth of digital healthcare market
BD, a leading global medical technology company, today announced that it will present at the following upcoming virtual investor conferences
Voluntis (Euronext Paris, Ticker: VTX – ISIN: FR0004183960), a leader in digital therapeutics, announced today the issuance of a new patent by the European Patent Office (EPO) for intelligent patient support in drug dosing applied in the field of diabetes for insulin titration support.
The Company update presentations will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.
BIOCORP today announces the signature of new partnerships with Health2Sync and SocialDiabetes, companies headquartered in Taiwan and Spain, respectively. These two partnerships involve the integration of Mallya, the connected device dedicated to insulin pens, with the digital applications developed by Health2Sync and SocialDiabetes to improve the quality of care for patients with diabetes.
#connected device
#insulin pen
#mobile app
Brighter AB has signed a five-year distribution agreement with Al Danah Medical Company in Qatar regarding Brighter’s pioneering product portfolio for diabetes management Actiste®. Both Actiste® and the newly developed Actiste® Mini are included in the agreement. With Qatar’s healthcare system being primarily state-run the outcome of the agreement will largely depend on the Distributor’s ability to win public tenders. Based on the distributor's experience and position in Qatar, Brighter is optimistic about the distributor's ability to win such contracts. Brighter will work closely with Al Danah to achieve this. The Distributor also has ambitions to market the Actiste® product portfolio through its chain of pharmacies.
#institution
#bgm
#insulin pen